NEWS

Synthetic horsepox virus could lead to more effective smallpox vaccine – Drug Target Review

Drug Target ReviewSynthetic horsepox virus could lead to more effective smallpox vaccineDrug Target ReviewDr Evans hopes the research will contribute to informed discussions relating to the potential applications of synthetic biology for the benefit of… Continue reading

Sterne, Kessler, Goldstein & Fox Elects Five New Directors – IPWatchdog.com

Sterne, Kessler, Goldstein & Fox Elects Five New DirectorsIPWatchdog.com… International Trade Commission investigations under §337, evaluating patent portfolios, drafting patent applications, and prosecuting interferences. He also manages the pre… Continue reading

Sterne, Kessler, Goldstein & Fox Elects Five New Directors – IPWatchdog.com

Sterne, Kessler, Goldstein & Fox Elects Five New DirectorsIPWatchdog.com… International Trade Commission investigations under §337, evaluating patent portfolios, drafting patent applications, and prosecuting interferences. He also manages the pre… Continue reading

Eureka Therapeutics Closes $60 Million in Series D Financing to Advance Proprietary ARTEMIS™ T Cell Receptor … – Business Wire (press release)

Eureka Therapeutics Closes $60 Million in Series D Financing to Advance Proprietary ARTEMIS™ T Cell Receptor …Business Wire (press release)This financing represents an important validation of our strategy, and provides us the resources to advance our… Continue reading

Not just a stem cell marker – Medical Xpress – Medical Xpress

Medical XpressNot just a stem cell marker – Medical XpressMedical XpressThe protein CD34 is predominantly regarded as a marker of blood-forming stem cells but it helps with migration to the bone marrow too.and more &raquo… Continue reading

Celgene is buying cancer drugmaker Juno Therapeutics for $9 billion – Markets Insider

Endpoints News

Celgene is buying cancer drugmaker Juno Therapeutics for $9 billion Markets Insider One challenge these therapies still face is how toxic they can be. CAR–T’s side effects can be deadly. In May 2017, Kite disclosed that one person had died in a clinical trial for its late-stage CAR–T therapy from cerebral edema, a condition in which … Celgene to buy Juno for $9 billion to boost CAR–T expertiseReuters UPDATED: Celgene bags CAR–T player Juno in $9B buyout as biotech M&A suddenly explodesEndpoints News Shares of biotech Juno, already up 50% on deal hopes, skyrocket on actual Celgene $9 billion offerCNBC Business Wire (press release) –Financial Times all 128 news articles »

Endpoints News

UPDATED: Celgene bags CAR–T player Juno in $9B buyout as biotech M&A suddenly explodes Endpoints News Leerink in particular was looking for Celgene to fork over $93 a share, which is what Celgene pegged the price at when it bought a minority share in the biotech. CAR-T has been one of the big success stories for biotech, offering a new approach to … Muscle CAR? Celgene’s $9B offer for Juno starts pundits weighing tractionBioWorld Online Celgene to buy Juno for $9 billion to boost cancer pipelineReuters Shares of biotech Juno, already up 50% on deal hopes, skyrocket on actual Celgene $9 billion offerCNBC Madison.com –Zacks Investment Research –Zacks Investment Research all 241 news articles »